Impact of a national nirsevimab programme on critical care transport of babies with bronchiolitis: a retrospective observational study Authors: Tara Moore, Ashfaq Afridi, Nurul H Aminudin, Cathy Gibbons, Orna Grant, Hana Fucikova, Carmel Maria Moore Published: 2026 Background Respiratory syncytial virus (RSV) is a leading cause of bronchiolitis, triggering annual epidemics that peak in autumn and winter and result in approximately three million hospitalisations globally each year. Severe bronchiolitis often requires admission to a paediatric intensive care unit (PICU), which can require interhospital transfer. More than half of bronchiolitis PICU admissions in Ireland during the 2023–2024 winter season were transferred from another hospital.1 RSV-related admissions to Children’s Health Ireland in 2023–2024 were estimated to have a financial cost of over €6 million.1 In Ireland, where possible, transfers into PICU are provided by the National Ambulance Service Critical Care Retrieval Service, staffed by specialist medical and nursing teams with dedicated ambulance resources. The National Neonatal Transport Programme provides a 24/7 service for babies under 28 days corrected, and the Irish Paediatric Acute Transport Service (IPATS) provides a 7-day daytime service from 28 days corrected to 16 years of age. When a child older than 28 days requires transport outside of IPATS hours, this is undertaken by local teams with frontline ambulance resources. Nirsevimab, a monoclonal antibody, provides 150–180 days of protection from RSV bronchiolitis.2 It was recommended for all newborns in Ireland from September 2024 to February 2025, at no cost to parents from all maternity units, with overall uptake in the first season of 83%.3 High-risk older infants were offered immunisation via a funded homecare service. Surveillance data demonstrated a 65% reduction in total RSV cases, a 57% reduction in emergency department RSV presentations, a 76% reduction in RSV hospitalisations and a 65% reduction in RSV PICU admissions.4 Methods We reviewed, with ethics committee approval, all critical care transport records of babies transferred during pre-nirsevimab and post-nirsevimab epochs September 2023–February 2024 and September 2024–February 2025. Results In the 2023 RSV season, pre-nirsevimab, 61 babies were transported with a diagnosis of bronchiolitis compared with 16 babies in the post-nirsevimab 2024 RSV season. Of these babies, 77% (n=47) in the 2023 season and 63% (n=10) in the 2024 season tested positive for RSV. Importantly, 80% (n=8) babies with RSV-positive bronchiolitis in the post-nirsevimab season had not received nirsevimab (see table 1). There was a similar age distribution of babies across both epochs (see table 2). Table 1Babies transported with bronchiolitisPre-nirsevimab (2023–2024)Post-nirsevimab (2024–2025)Babies with bronchiolitis transported6116Babies with RSV bronchiolitis transported47 (77%)10 (63%)Babies with RSV who did not receive nirsevimab8 (80%)Babies transported on invasive ventilation24 (39%)4 (25%)Babies with RSV requiring invasive ventilation6 (10%)1 (6%)Babies transported on HHFNC14 (23%)6 (38%)Babies transported on CPAP20 (33%)5 (31%)Babies transported on BiPAP3 (5%)1 (6%)Babies who required ventilatory support escalation by transport team17 (28%)3 (19%)Babies who required intubation by transport team10 (16%)2 (13%)Total time spent on transport388 hours 26 min101 hours 8 minBiPAP, bilevel positive airway pressure; CPAP, continuous positive airway pressure; HHFNC, humidified high flow nasal cannula; RSV, respiratory syncytial virus. Babies transported with bronchiolitis BiPAP, bilevel positive airway pressure; CPAP, continuous positive airway pressure; HHFNC, humidified high flow nasal cannula; RSV, respiratory syncytial virus. Table 2Age distribution of babies20232024Preterm11 (18%)4 (25%)0–1 months27 (44%)7 (44%)1–2 months11 (18%)1 (6%)2–3 months10 (16%)2 (13%)3–4 months1 (2%)1 (6%)4–5 months1 (2%)1 (6%)5–6 months00Total6116 Age distribution of babies Total time spent on transport of babies with bronchiolitis by the transport teams reduced from 388 hours 26 minutes in the 2023 season to 101 hours and 8 minutes in the 2024 season. Limitations This study does not capture babies transferred by the referring hospital to critical care. Comparing only two epochs may miss annual variation in RSV prevalence. Conclusion We have shown a 74% reduction in the total number of babies with bronchiolitis transferred by critical care transport services in Ireland after the implementation of a national nirsevimab programme, with a 79% reduction in babies with RSV-positive bronchiolitis transported. Of note, 80% of the babies who were transferred with RSV-positive bronchiolitis had not received nirsevimab. Barriers to parental acceptance of nirsevimab should be explored. Footnotes Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors. Patient consent for publication: Not applicable. Ethics approval: This study involves human participants and was approved by Rotunda Hospital Research Advisory Group (RAG 2025-008) and Children’s Heath Ireland Research Ethics Committee (REC-611-25). Provenance and peer review: Not commissioned; externally peer reviewed. Data availability statement Anonymised data only were collected and analysed. References Associated Data Data Availability Statement Anonymised data only were collected and analysed.